tiprankstipranks
Aerovate Therapeutics (AVTE)
NASDAQ:AVTE
US Market

Aerovate Therapeutics (AVTE) Income Statement

Compare
126 Followers

Aerovate Therapeutics Income Statement

Last quarter (Q3 2024), Aerovate Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, Aerovate Therapeutics's net income was $-16.24M. See Aerovate Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ -96.00K$ -68.00K$ -15.00K$ -1.00K$ 0.00
Operating Expenses
$ 81.41M$ 53.24M$ 23.02M$ 8.89M$ 3.33M
Depreciation and Amortization
$ 96.00K$ 68.00K$ 15.00K$ 1.00K$ 3.33M
EBITDA
$ -81.31M$ -53.17M$ -23.01M$ -8.89M$ 1.00K
Operating Income
$ -81.41M$ -53.24M$ -23.02M$ -8.89M$ -3.33M
Other Income/Expenses
$ 5.94M$ 1.75M$ 62.00K$ -722.00K$ 2.00K
Pretax Income
$ -75.47M$ -51.49M$ -22.96M$ -9.61M$ -3.33M
Net Income
$ -75.52M$ -51.51M$ -22.96M$ -9.04M$ -3.33M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ -2.87$ -2.10$ -0.94$ -0.37$ -0.14
Diluted EPS
$ -2.87$ -2.10$ -0.94$ -0.37$ -0.14
Weighted Average Shares Outstanding
26.33M 24.47M 24.41M 24.41M 24.41M
Weighted Average Shares Outstanding (Diluted)
26.33M 24.47M 24.41M 24.41M 24.41M
Currency in USD

Aerovate Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis